March 17 (Reuters) - The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said on Tuesday, sending its shares down 65% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results